Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Citizens analyst Silvan Turkcan initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Market Outperform rating and announces Price Target of $51.
Citizens analyst Silvan Turkcan initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Market Outperform rating and announces Price Target of $51.